Dedicating to innovation, practicing to achieve targets: interpretation of research & innovation part of the WHO Global Tuberculosis Report 2023

doi:10.19982/j.issn.1000-6621.20240159

Abstract

Abstract:

“Intensified research and innovation” is the third pillar of the End TB Strategy, new research and technology are important tools to accelerate the process of eliminating tuberculosis (TB). On November 7, 2023, World Health Organization released the Global Tuberculosis Report 2023, updating the global prevalence of TB and the progress in the prevention, diagnosis and treatment. This paper reviews the key achievements in the areas of TB research and innovation for new diagnostics, drugs and regimens as well as vaccines introduced in the report, and discusses some of China’s indigenous progresses in related areas. This paper aims to make China’s TB professionals better informed about the latest research development in TB prevention and control around the globe, fostering indigenous TB innovation efforts with greater originality.

Key words: Tuberculosis, Research, Consensus development conference

CLC Number:

Shu Wei, Liu Yuhong. Dedicating to innovation, practicing to achieve targets: interpretation of research & innovation part of the WHO Global Tuberculosis Report 2023[J]. Chinese Journal of Antituberculosis, 2024, 46(6): 613-617. doi: 10.19982/j.issn.1000-6621.20240159

References 18

[1]	舒薇, 刘宇红. 世界卫生组织《2023年全球结核病报告》解读. 结核与肺部疾病杂志, 2024, 5(1): 15-19. doi:10.19983/j.issn.2096-8493.2024006.
[2]	World Health Organization. The Global Strategy for TB research and innovation. Geneva: World Health Organization, 2020.
[3]	World Health Organization. WHO TB Knowledge Sharing Platform. Geneva: World Health Organization, 2023.
[4]	United Nations. Resolution 73/3: Political declaration of the high-level meeting of the General Assembly on the fight against tuberculosis. New York: United Nations, 2018.
[5]	Treatment Action Group. Tuberculosis research funding trends 2005—2021. New York: Treatment Action Group, 2022.
[6]	张立杰, 刘宇红. 联合国大会第二届结核病防治高级别会议政治宣言解读. 中国防痨杂志, 2023, 45(12): 1117-1119. doi:10.19982/j.issn.1000-6621.20230380.
[7]	General Assembly of the United Nations. Political Declaration of the High-Level Meeting on the Fight against Tuberculosis:draft resolution/submitted by the President of the General Assembly. New York: General Assembly of the United Nations, 2023.
[8]	World Health Organization. Use of targeted next-generation sequencing to detect drug-resistant tuberculosis Rapid communication, 2023. Geneva: Word Health Organization, 2023.
[9]	黄海荣. 世界卫生组织《应用新一代靶向测序技术检测耐药结核病:快速通告,2023》解读. 中国防痨杂志, 2023, 45(10): 921-924. doi:10.19982/j.issn.1000-6621.20230311.
[10]	Nyang’wa BT, Berry C, Kazounis E, et al. Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial. Lancet Respir Med, 2024, 12(2):117-128. doi:10.1016/S2213-2600(23)00389-2.
[11]	Guglielmetti L. End TB trial: Safety results in a study of five shortened, all-oral regimens for MDR/RR-TB. Int J Tuberc Lung Dis, 2023: S1.
[12]	Khan U. End TB trial: Efficacy results in a study of fiveall-oral, shortened regimens for MDR/RR-TB. Int J Tuberc Lung Dis, 2023: S1.
[13]	Goodall R. Long-term outcomes in STREAM Stage 2: A phase 3 trial in rifampicin-resistant TB. Int J Tuberc Lung Dis, 2023: S80.
[14]	Burhan E. Summary of the main TRUNCATE-TB trial results and outstanding questions. Int J Tuberc Lung Dis, 2023: S14.
[15]	Boeree MJ, Heinrich N, Aarnoutse RE. Treatment Strategy for Rifampin-Susceptible Tuberculosis. N Engl J Med, 2023, 388(24): 2297. doi:10.1056/NEJMc2304776.
[16]	Jindani A, Atwine D, Grint D, et al. Four-Month High-Dose Rifampicin Regimens for Pulmonary Tuberculosis. NEJM Evid, 2023, 2(9): EVIDoa2300054. doi:10.1056/EVIDoa2300054.
[17]	World Health Organization. Use of bedaquiline in children and adolescents with multidrug- and rifampicin-resistant tuberculosis: information note. Geneva: Word Health Organization, 2023.
[18]	World Health Organization. Use of delamanid in children and adolescents with multidrug- and rifampicin-resistant tuberculosis: information note. Geneva: Word Health Organization, 2023.